Table 2.
Proportional Hazards Model with Time-Dependent Variable for Treatment Categories.
| Overall Survival | Lung Cancer-Specific Survival | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Variable | HR | 95%CI | P>X2 | HR | 95%CI | P>X2 |
| Treatment (t ≤ 6 Months) | ||||||
| Lobectomy (baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| Sublobar Resection | 0.95 | (0.86 to 1.05) | 0.31 | 1.07 | (0.91 to 1.25) | 0.42 |
| SABR | 0.48 | (0.38 to 0.63) | <.001 | 0.59 | (0.36 to 0.96) | 0.03 |
| Conventional XRT | 1.22 | (1.09 to 1.36) | <.001 | 1.65 | (1.39 to 1.95) | <.001 |
| Observation | 22.6 | (19.9 to 25.7) | <.001 | 28.8 | (23.8 to 34.6) | <.001 |
| Treatment (t > 6 Months) | ||||||
| Lobectomy (baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| Sublobar Resection | 1.40 | (1.28 to 1.54) | <.001 | 1.55 | (1.33 to 1.82) | <.001 |
| SABR | 1.56 | (1.21 to 2.00) | <.001 | 1.81 | (1.11 to 2.95) | 0.02 |
| Conventional XRT | 2.65 | (2.38 to 2.96) | <.001 | 3.50 | (2.96 to 4.13) | <.001 |
| Observation | 2.18 | (1.93 to 2.46) | <.001 | 3.01 | (2.51 to 3.60) | <.001 |
| Age | 1.02 | (1.02 to 1.03) | <.001 | 1.01 | (1.00 to 1.02) | 0.002 |
| Race | ||||||
| White | 1.00 | -- | -- | 1.00 | -- | -- |
| Black/Other | 0.98 | (0.89 to 1.08) | 0.70 | 0.95 | (0.82 to 1.09) | 0.51 |
| Gender | ||||||
| Male | 1.00 | -- | -- | 1.00 | -- | -- |
| Female | 1.27 | (1.21 to 1.34) | <.001 | 1.25 | (1.16 to 1.36) | <.001 |
| Charleson Comorbidity Score | ||||||
| 0 (Baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| 1 | 1.26 | (1.18 to 1.34) | <.001 | 1.16 | (1.05 to 1.27) | 0.002 |
| ≥2 | 1.59 | (1.50 to 1.70) | <.001 | 1.25 | (1.16 to 1.35) | <.001 |
| Missing | 1.23 | (1.07 to 1.41) | 0.003 | 1.03 | (0.84 to 1.25) | 0.80 |
| Size | ||||||
| 0.0–2.9 cm (Baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| 2.1 – 3.0 cm | 1.23 | (1.16 to 1.30) | <.001 | 1.40 | (1.27 to 1.54) | <.001 |
| 3.1 – 5.0 cm | 1.47 | (1.38 to 1.57) | <.001 | 1.82 | (1.65 to 2.00) | <.001 |
| Grade (High v. Other) | ||||||
| High | 1.00 | -- | -- | 1.00 | -- | -- |
| Other | 1.07 | (1.01 to 1.13) | 0.02 | 1.11 | (1.01 to 1.21) | 0.03 |
| Nodal Sampling | ||||||
| Performed | 1.00 | -- | -- | 1.00 | -- | -- |
| Not Performed | 0.80 | (0.73 to 0.88) | <.001 | 0.77 | (0.67 to 0.89) | <.001 |
| Histology | ||||||
| NSCLC, nos (Baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| Adenocarcinoma | 0.92 | (0.85 to 0.99) | 0.03 | 0.88 | (0.79 to 0.99) | 0.03 |
| Squamous carcinoma | 1.12 | (1.04 to 1.22) | 0.003 | 1.08 | (0.97 to 1.20) | 0.17 |
| Large cell | 1.02 | (0.89 to 1.17) | 0.82 | 1.04 | (0.86 to 1.26) | 0.72 |
| PET Imaging | ||||||
| Not Performed | 1.00 | -- | -- | |||
| Performed | 0.91 | (0.87 to 0.96) | <.001 | 0.84 | (0.78 to 0.91) | <.001 |
| Income | ||||||
| First Quartile (Baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| Second Quartile | 1.04 | (0.97 to 1.12) | 0.29 | 1.04 | (0.93 to 1.16) | 0.49 |
| Third Quartile | 0.99 | (0.91 to 1.07) | 0.77 | 0.94 | (0.83 to 1.06) | 0.32 |
| Fourth Quarile | 0.95 | (0.86 to 1.06) | 0.36 | 0.89 | (0.76 to 1.03) | 0.12 |
| Educational Level | ||||||
| First Quartile (Baseline) | 1.00 | -- | -- | 1.00 | -- | -- |
| Second Quartile | 1.01 | (0.93 to 1.09) | 0.84 | 1.07 | (0.95 to 1.21) | 0.28 |
| Third Quartile | 1.05 | (0.96 to 1.14) | 0.28 | 1.07 | (0.93 to 1.22) | 0.34 |
| Fourth Quartile | 1.15 | (1.04 to 1.27) | 0.005 | 1.15 | (0.99 to 1.34) | 0.07 |
Abbreviations: HR, hazard ratio; CI, confidence interval; SABR, stereotactic ablative radiation; XRT, radiation; NSCLC, NOS, non-small cell lung cancer, not otherwise specified; PET, positron emission tomography